New Modalities for the Treatment of Pain and Drug Abuse

治疗疼痛和药物滥用的新方法

基本信息

  • 批准号:
    9073233
  • 负责人:
  • 金额:
    $ 53.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-05-01 至 2022-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): While much has been learned about the neurobiology of pain, it is disappointing that an insufficient number of novel therapies have been introduced into clinical practice. Moderate to severe pain is still treated mechanistically with opiate mu agonists and while some new mechanisms and improved formulations have improved patient care, it is widely acknowledged that the armamentarium available to physicians for the treatment of chronic pain is inadequate and that there is a large unmet medical need. The significance of our application is to address the clinical need for medications for injury or disease-induced chronic non-malignant pain with new mechanisms of action. Our goals in this PPG proposal are driven by the need of patients for new therapies to control pain as well as issues relevant to society including addiction and drug abuse. The proposals we have developed are comprehensive, multidisciplinary, and emphasize novel research hypotheses. This application brings together state-of-the-art chemistry, pharmacology, biophysics, biochemistry, and molecular biology all of which are necessary for success. Our central hypothesis is that drug design can consider known neural adaptations and mechanisms that may be relevant to specific pain conditions in order to develop improved pain therapeutics. We propose to design, synthesize and biologically validate multivalent drugs that can act as analgesics for the prolonged treatment of chronic non-malignant pain. The multifunctional characteristics of these single molecules are hypothesized to demonstrate diminished likelihood of drug addiction, drug seeking behavior, and tolerance without, or with greatly reduced, side effects that are present in currently available drugs and that diminish quality of life. Project A will be directed by Professo Victor Hruby and will focus on the discovery of multivalent opioid mu agonist-delta agonist and mu agonist/NK1 antagonist peptidic molecules with drug like characteristics and penetration across the blood brain barrier for delivery by systemic administration. Project B will be directed by Professors Frank Porreca and Ed Roberts and will aim to discover orally available and brain penetrant opioid mu/CCK antagonist molecules with drug like characteristics. Project C will be directed by Professors Alex Makriyannis, Todd Vanderah and Frank Porreca and will explore multifunctional cannabinoid agonists for improved treatment of HIV neuropathic pain. These projects will be supported by an Administrative Core (Hruby/Porreca), a synthetic core (Hruby) and a Biochemical Core (Vanderah/Streicher) that will allow maximal synergy and progress. Our goals are to discover single molecules with multiple receptor characteristics that have drug-like properties allowing for advancement to human trials for improved treatment of pain.
描述(由申请人提供):虽然已经了解了很多关于疼痛的神经生物学,但令人失望的是,临床实践中引入的新疗法数量不足。中度至重度疼痛仍采用阿片μ受体激动剂进行机械治疗,虽然一些新的机制和改进的制剂改善了患者护理,但人们普遍认为,医生可用于治疗慢性疼痛的医疗设备不足,存在大量未满足的医疗需求。我们申请的意义在于解决临床上对具有新作用机制的损伤或疾病引起的慢性非恶性疼痛药物的需求。我们在PPG提案中的目标是由患者对控制疼痛的新疗法的需求以及与社会相关的问题(包括成瘾和药物滥用)驱动的。我们已经制定的建议是全面的,多学科的,并强调新颖的研究假设。该应用程序汇集了最先进的化学,药理学,生物物理学,生物化学和分子生物学,所有这些都是成功所必需的。我们的中心假设是,药物设计可以考虑已知的神经适应和机制,可能与特定的疼痛条件,以开发改进的疼痛治疗。我们建议设计,合成和生物学验证多价药物,可以作为长期治疗慢性非恶性疼痛的镇痛药。这些单分子的多功能特性被假设为证明药物成瘾、药物寻求行为和耐受性的可能性降低,而没有或大大降低了目前可用药物中存在的降低生活质量的副作用。项目A将由Elisso维克托Hruby指导,并将专注于发现多价阿片类μ激动剂-δ激动剂和μ激动剂/NK 1拮抗剂肽分子,其具有药物样特征并穿透血脑屏障,可通过全身给药递送。项目B将由Frank Porreca教授和艾德罗伯茨教授指导,旨在发现具有药物样特征的口服和脑渗透阿片类mu/CCK拮抗剂分子。项目C将由Alex Makriyannis、托德·范德拉和弗兰克·波雷卡教授指导,并将探索多功能大麻素激动剂,以改善艾滋病毒神经性疼痛的治疗。这些项目将得到一个行政核心(Hruby/Porreca)、一个合成核心(Hruby)和一个生化核心(Vanderah/Streicher)的支持,这些核心将实现最大的协同作用和进展。我们的目标是发现具有多种受体特征的单一分子,这些分子具有药物样特性,可以推进到人类试验,以改善疼痛的治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Victor J Hruby其他文献

Victor J Hruby的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Victor J Hruby', 18)}}的其他基金

New Modalities for the Treatment of Pain and Drug Abuse
治疗疼痛和药物滥用的新方法
  • 批准号:
    9918285
  • 财政年份:
    2017
  • 资助金额:
    $ 53.77万
  • 项目类别:
Design of Novel Multivalent Ligands with Unique Biological Activity Profiles for Treatment of Prolonged and Neuropathic Pain without Toxicities
具有独特生物活性特征的新型多价配体的设计,用于无毒治疗长期疼痛和神经性疼痛
  • 批准号:
    9073237
  • 财政年份:
    2017
  • 资助金额:
    $ 53.77万
  • 项目类别:
SYNTHESIS CORE
综合核心
  • 批准号:
    8025973
  • 财政年份:
    2010
  • 资助金额:
    $ 53.77万
  • 项目类别:
DESIGN OF NOVEL LIGANDS WITH UNIQUE BIOLOGICAL PROFILES FOR NEUROPATHIC PAIN AND
设计具有独特生物特征的新型配体,用于治疗神经病理性疼痛和
  • 批准号:
    8025975
  • 财政年份:
    2010
  • 资助金额:
    $ 53.77万
  • 项目类别:
ADMINISTRATIVE CORE
行政核心
  • 批准号:
    8025972
  • 财政年份:
    2010
  • 资助金额:
    $ 53.77万
  • 项目类别:
Core - Synthesis Core
核心 - 综合核心
  • 批准号:
    7513590
  • 财政年份:
    2007
  • 资助金额:
    $ 53.77万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    7513589
  • 财政年份:
    2007
  • 资助金额:
    $ 53.77万
  • 项目类别:
Design of Novel Opiod Peptide Ligands With Unique Biological Profiles
具有独特生物学特征的新型阿片肽配体的设计
  • 批准号:
    7513577
  • 财政年份:
    2007
  • 资助金额:
    $ 53.77万
  • 项目类别:
Multimeric Ligands for Targeting Melanoma
用于靶向黑色素瘤的多聚配体
  • 批准号:
    8288314
  • 财政年份:
    2003
  • 资助金额:
    $ 53.77万
  • 项目类别:
Multimeric Ligands for Targeting Melanoma
用于靶向黑色素瘤的多聚配体
  • 批准号:
    8396604
  • 财政年份:
    2003
  • 资助金额:
    $ 53.77万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 53.77万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 53.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 53.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 53.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 53.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 53.77万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 53.77万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 53.77万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 53.77万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 53.77万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了